Exxel Pharma to Participate in a 'New to Virtual Investor' Segment
Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced that it will participate in a "New to Virtual Investor" segment on Wednesday, February 5, 2025 at 4:00 PM ET.
As part of the event, Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel Pharma, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Investors page of the Company's website (exxelpharma.com). Viewers can also access the event on the Virtual Investor website at virtualinvestorco.com.
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity disorders. The Company's lead program, EX937, is a first-in-class, orally administered, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies, EX937 demonstrated robust efficacy in modulating chronic cough across multiple models. Furthermore, it has shown a favorable safety profile and is designed to avoid central side effects by being entirely excluded from the brain. EX937 also holds promise for a range of high-value indications, including hyperactive bladder, peripheral painful neuropathies, and migraine headaches. In addition to EX937, Exxel Pharma is advancing its ARN compounds, a second lead program targeting social anxiety disorder and autism spectrum disorder.
Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: exxel@jtcir.com
SOURCE: Exxel Pharma, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
CEA Industries Posts Updated Investor Presentation
Conference Call Scheduled for Today, June 11, 2025 at 4:30pm ET CEA Industries to Provide Business Update and Discuss Strategic Implications of Fat Panda Acquisition Louisville, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: CEAD, CEADW) ('CEA Industries' or the 'Company'), today announced that it has published an updated investor presentation, now available on the Investor Relations section of its website. Management will host a live conference call today, June 11, 2025, at 4:30pm ET to outline the Company's new strategic priorities, including the recent acquisition of Fat Panda and the go-forward strategy to accelerate growth and enhance shareholder value. To access the conference call, please use the following information: Dial-in: 1-973-528-0008 Access Code: 891969 Webcast URL: CEA Industries management may utilize this presentation during upcoming meetings with analysts and investors. The posting of this presentation is being made pursuant to Regulation FD. About CEA Industries Inc. CEA Industries Inc. (NASDAQ: CEAD) is a growth-oriented company focused on building category-leading businesses in regulated consumer markets. With a focus on the high-growth, Canadian nicotine vape industry, one of the fastest-expanding segments of the global nicotine market, CEA Industries targets scalable operators with strong regulatory alignment, defensible market share, and high-margin business models. The Company provides capital, operational expertise, and strategic resources to accelerate retail expansion, strengthen e-commerce infrastructure, and drive long-term value creation in performance-driven sectors. For more information, visit Investor Contact: Sean Mansouri, CFA or Aaron D'SouzaElevate IRinfo@ (720) 330-2829Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C., June 11, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 million and $80 million The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 2, 2025. Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results. "Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations. "To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization—transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities. "These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements. "Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space," concluded O'Connor. Third Quarter Fiscal 2025 Press Release, Webcast, and Conference Call Details The Company will report third quarter fiscal 2025 financial results after the market close on Wednesday, July 2, 2025. Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus' performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website where it will also be available for replay approximately one hour following the call. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Preliminary Financial Results and Financial Guidance The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP. In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
an hour ago
- WebMD
FDA Approves New 3-in-1 Combo Pill for High Blood Pressure
June 11, 2025 – The FDA has approved a new pill for adults with high blood pressure (hypertension) that combines three medicines in one. Available in one regular and two lower doses, it offers a convenient option for treating hypertension, which affects nearly half of the adults in the U.S. and raises their risk of stroke and heart failure. Sold as Widaplik, it is the first and only single pill to combine three previously FDA-approved drugs – telmisartan, amlodipine, and indapamide – offering a triple-action approach for people who would otherwise need multiple pills to manage their blood pressure. It works in three ways and is a safe, well-tolerated early treatment option. Hypertension happens when your blood pushes too hard against your blood vessels, making the heart work harder and increasing the risk of heart problems, strokes, and other complications. It contributes to about 460,000 deaths annually in the U.S. and often goes undetected due to a lack of symptoms. With 1 in 3 Americans unaware they have it and only 1 in 4 managing it well, there's an urgent need for simpler, more effective treatments. The approval was based on two large studies that showed using Widaplik helped lower blood pressure more than using just two medicines or a placebo, according to a news release from the company that makes it, George Medicines. People who took Widaplik didn't stop taking it more often because of side effects, which means it was generally easy for them to take. Another trial showed that Widaplik was better at reducing blood pressure compared to standard care, while remaining well-tolerated. George Medicines stated that a global trial is underway to find out if the combo treatment can help prevent strokes in people who have previously had an intracerebral hemorrhage (sudden bleeding in the brain), the most serious type of stroke. "Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide. Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment," Paul Whelton, MD, Show Chwan chair of global public health at Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. Widaplik is a medicine made of three drugs that work together to help lower blood pressure. Two of them, telmisartan and amlodipine, relax blood vessels so blood can flow more easily. The third, indapamide, helps your body get rid of extra water by making you pee more. Widaplik comes in three strengths: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Low blood pressure – which can make you feel faint or dizzy – was the most common side effect, the company said. Patients who pass out should stop taking the medication and consult their doctor.
